- Home
- HLP vs IMA Comparison
HLP vs IMA Comparison
Compare HLP & IMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HLP | IMA |
|---|---|---|
| Founded | 2021 | 2019 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.4M | 65.4M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | HLP | IMA |
|---|---|---|
| Price | $1.07 | $6.72 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 130.2K | 48.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $51.63 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.61 | $5.70 |
| 52 Week High | $1.72 | $17.50 |
Technical Indicators
Market Signals| Indicator | HLP | IMA |
|---|---|---|
| Relative Strength Index (RSI) | 54.27 | 45.97 |
| Support Level | $0.67 | $6.65 |
| Resistance Level | $1.65 | $7.14 |
| Average True Range (ATR) | 0.16 | 0.44 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 31.94 | 14.42 |
Price Performance
Historical ComparisonAbout HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.
About IMA ImageneBio Inc.
ImageneBio Inc is a clinical-stage biopharmaceutical company that develops differentiated therapies for immunological and inflammatory (I&I) diseases. The company is focused on developing IMG-007, a non-depleting anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis.